OZEM241220C26000
- 1.85
- 0.000.00%
Roundhill GLP-1 & Weight Loss ETF Newsroom
Trump's return is bullish for growth stocks, with these 10 having the greatest upside potential.
Jefferies financial strategists expect that Trump's re-election as president will encourage investors to continue pursuing growth stocks, suggesting that investors avoid value stocks.
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
The new version of the medical insurance list adds 11 Chinese patent medicine varieties. Traditional Chinese medicine innovative drugs, classic famous prescriptions, and children's medications receive key support.
In 2024, the national medical insurance catalog was officially released today, with 91 pharmaceuticals newly added to the national medical insurance drug catalog, with an average price reduction of 63%; this time there are 11 new chinese patent medicines added, 10 of which are new drugs approved for marketing last year and this year.
How to adjust the new national medical insurance catalog? Here is the explanation.
1. The success rate is 76%, with an average decline of 63%. This year, the success rate and decline of negotiating/bidding pharmaceuticals are basically equivalent to previous years; 2. This year, the fund calculation will pay more attention to the impact on fund expenditure, while also enhancing the comprehensiveness and scientific nature of the calculation work; 3. This year's catalog adjustment places more emphasis on the actual clinical needs and patients' actual medication, highlighting support for true innovation.
The Trump economic team may have internal discord, and the key agenda still needs the "understanding king" to make the final decision!
Analysts state that the Trump team's characterization of the economic policy as 'the opponent team' is almost accurate, and the strong opposition between Besant and Lutnik has been publicly reported.
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Novo Nordisk Says Health Canada Approves Wegovy (Semaglutide Injection) To Reduce Risk Of Non-Fatal Myocardial Infarction
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Temporarily drops below the key level of 38,000 yen due to caution over Trump tariffs.
The Nikkei Average continued to decline. It closed the trading at 38,134.97 yen, down 307.03 yen (trading volume estimated at 1.82 billion shares). Today, due to concerns about the future of the global economy against the backdrop of the Trump administration's strengthened tariffs, selling pressure for risk aversion persisted. Additionally, the yen's appreciation, temporarily reaching the 152 yen to the dollar range, also had a negative impact on export-related stocks. As a result, the Nikkei Average widened its decline towards the end of the afternoon session, reaching 37,988.99 yen, breaking below the psychological milestone of the 38,000 yen level.
Active and newly listed stocks during the morning session.
*Dai Do Group HD <2590> 3240 +326 The cumulative operating profit for the third quarter has turned into an increase. *Janome <6445> 1187 +82 The stock remains strong, and buybacks are becoming more active. *Keisei Electric Railway <9009> 4662 +243 Viewed the sale of OLC shareholding as a catalyst. *Resonac <4004> 4170 +178 Interest as related to perovskite solar cells. *Oriental Land Co., Ltd. Unsponsored ADR <4661> 3585 +150 Responding to the sale of shareholding in Keisei Electric Railway.
Futu Morning Report | The US stock market party continues! The s&p 500 index has risen for seven consecutive days, setting a new historical high; Federal Reserve meeting minutes: future interest rate cuts will be cautious, and the end of monetary easing i
Market response to Trump's tariff threats: auto stocks wail, the Canadian dollar hits a four-year low, and the Mexican peso plunges nearly 3%; dell technologies drops over 10% after hours, with total net revenue for the third quarter at 24.37 billion USD, below analyst expectations.
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert
Amgen weight loss drugs have a remarkable effect of reducing 20% body weight, but with relatively high side effects, leading to a temporary large drop of over 12% during trading hours.
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
US stocks closed | The three major indices rose together, with Dow Jones and S&P hitting new highs; tariff threats dragged down auto stocks, general motors fell 9%
Waiting for PCE inflation, the Fed's November minutes support gradual rate cuts, temporarily suppressing US bond yields and the dollar while gold rallies. The Dow turns higher at the end of the day, hitting new highs for three consecutive days, while small cap stocks fall from the highest level in six days, with chip stocks down more than 1%, but nvidia rebounds by 0.7%. Tesla reverses its decline, Nio falls by 7.7%, Amgen's weight loss drug once fell by more than 12%, and Dell falls more than 9% after hours.
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
The Biden administration has proposed covering weight loss medications under Medicare, while Trump's team may become the biggest obstacle.
①The Biden administration has proposed expanding the coverage of federal medical care and medical subsidies to include weight loss drugs; ②The White House claims that these drugs can prevent type 2 diabetes, lower the risk of cardiovascular diseases such as heart disease, but currently they are too expensive for Americans. ③This proposal may be blocked by the Trump administration taking office next year, as Senator Kennedy opposes weight loss drugs.
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
Eli Lilly Stock Is Rising Tuesday: What's Going On?
Anavex Gains After Seeking EU Marketing Nod for Alzheimer's Drug
FOMC meeting minutes incoming, US stock index futures show mixed movements | Highlights tonight
1. Intel has locked in $7.9 billion in US chip subsidies for advanced chip factories; 2. Rivian has secured a $6.6 billion conditional loan commitment from the US Department of Energy, planning to build in the US; 3. The Federal Reserve will release the minutes of the November meeting at 3 am Beijing time on Wednesday.